A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates for Black vs White beneficiaries with early-stage NSCLC (all P<.001).

Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies considerably by race, even though 3 decades have passed since researchers first ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...

A leading hospital in Kenya has launched an artificial intelligence-powered radiotherapy system, expanding advanced cancer treatment options in a region ...